- For
- Longevity and telomere support
- Form
- SubQ injection (5-10 mg)
- Dose
- 5-10 mg / day
- Cycle
- 10 days, repeat every 4-6 months
- Safety
- Avoid with active cancer or pregnancy
- Legal
- Research peptide, not FDA-approved
Bottom line: A longevity research peptide with interesting animal telomere data and almost no human proof. Read about it; don't start here.
Safety at a glance
- Status: Not FDA-approved; research peptide. Human evidence is minimal.
- Evidence: Mostly animal; minimal human data.
- Do not use if: you have active cancer, or you are pregnant or breastfeeding.
- Not medical advice - decide this with a licensed physician.
What it does - plain English
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide (a peptide made of four amino acids) developed at the St. Petersburg Institute of Bioregulation and Gerontology in Russia in the 1980s. It is a synthesized version of a peptide your pineal gland (a small gland deep in your brain that helps regulate sleep and aging) makes naturally.
The Russian research claims it activates telomerase (an enzyme that maintains the protective caps on the ends of your chromosomes - caps that get shorter as you age) and improves sleep quality. The longevity community treats it as a longevity-promoting peptide.
The catch: most of the supportive research comes from one Russian lab, and Western replication is sparse.
What people use it for
A Watch-tier longevity peptide from the Russian lineage. Where people focus it:
Status
B-tier / Watch. The biological mechanism (telomerase activation, pineal-gland modulation) is plausible. The aging-trial evidence from Khavinson's lab is interesting - long-term cohort data shows mortality reductions in elderly subjects. But Western researchers haven't independently replicated the human trials, and the Russian methodology has limitations.
If you're researching longevity peptides, Epitalon is a worth-knowing entry. If you're starting a peptide protocol, it's not the first one to try.
Legal status
Epitalon is not FDA-approved. It sits in the same research-peptide gray zone as BPC-157 and TB-500. Compounding pharmacies in the US almost never dispense it. Most users source from research peptide vendors as research material.
Where to source
Research peptide vendors with a COA (Certificate of Analysis - a third-party lab report proving purity and dose) only. No COA, no buy. Period.
Compounding pharmacies generally don't carry it. If a US telehealth provider offers an Epitalon protocol, ask hard questions about sourcing. Most legitimate paths involve direct vendor relationships and third-party testing.
Subscribe below to get vendor reviews and price snapshots in the weekly dispatch.
New to peptides? Start with the foundations ->
Two studies worth reading
The mortality cohort
Khavinson et al., Bulletin of Experimental Biology and Medicine
One of the foundational Khavinson papers showing Epitalon's effect on cellular aging markers. Important context: the bulk of Epitalon's evidence base traces back to this lab, which is both a strength (consistent methodology) and a weakness (one source, limited Western replication).
Telomerase activation in vitro
Khavinson et al., Neuro Endocrinology Letters
In-vitro evidence that Epitalon activates telomerase in human somatic (non-reproductive) cells, which would theoretically slow aging. The mechanism paper that motivates the longevity-community interest.
Watch: Huberman on peptides (June 2026)
Huberman's June 2026 episode with Dr. Abud Bakri covers epithalon (epitalon) and the pineal longevity peptides, and he is explicit that no clinical trials point to a dose that extends human life. The animal logic is interesting; the human evidence is not there yet.
Source: Huberman Lab - Peptides: The Science, Uses & Safety (Dr. Abud Bakri). See our full decode of what he says about every peptide.
Last reviewed · 2026·06·04 · Status reviewed weekly